Quanterix

• Air pollution is associated with sex-specific longitudinal changes in astrocytic and neuroinflammatory processes linked to cognitive decline in Alzheimer's disease at-risk individuals

  Consulting or advice, Board or leadership role, 1 Oct 2026

• A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease

  Fees or honoraria, 21 Sept 2026

• A scalable workflow using digital cognitive assessment and pTau217 for MCI detection

  Consulting or advice, Fees or honoraria, Grants or research support, 17 Sept 2026

• Circulating Metabolite Signatures Associated With Amyloid Positivity, Cognitive Performance and Plasma P-tau181 Levels in Cognitively Unimpaired Older Adults

  Consulting or advice, Board or leadership role, 14 Sept 2026

• Parental longevity and polygenic longevity scores in relation to ageing-related factors in a population of 70-year-olds followed over six years: The Gothenburg H70 Birth Cohort Study

  Consulting or advice, Board or leadership role, 11 Sept 2026

• Sociodemographic and clinical characteristics of participants in blood p-tau217 studies for Alzheimer's disease: A systematic review

  Fees or honoraria, 10 Sept 2026

• Integrating frailty into decision-making for disease-modifying therapies in Alzheimer's disease: a proposed expert-opinion based approach

  Fees or honoraria, 4 Sept 2026

• Blood-based biomarkers of Alzheimer's disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms

  Consulting or advice, Board or leadership role, 2 Sept 2026

• Technology-natives and technology-adopters: Age differences in remote cognitive assessment in Alzheimer disease

  Consulting or advice, Fees or honoraria, 1 Sept 2026

• Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing

  Consulting or advice, Fees or honoraria, 24 Aug 2026

• Regional amyloid accumulation, post-traumatic distress, and intrusive symptoms in cognitively unimpaired older adults at risk for Alzheimer's

  Consulting or advice, Fees or honoraria, 18 Aug 2026

• Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers

  Consulting or advice, Board or leadership role, 12 Aug 2026

• Intensive versus standard blood pressure control and overall brain small vessel disease burden: a post-hoc analysis of the SPRINT randomized clinical trial

  Consulting or advice, Fees or honoraria, 11 Aug 2026

• Plasma Biomarkers for Neocortical Tau Burden

  Consulting or advice, Fees or honoraria, Board or leadership role, 10 Aug 2026

• Astrocyte reactivity modifies the effects of locus coeruleus norepinephrine-related dysfunction on tau and its impact on cognition

  Consulting or advice, Board or leadership role, 1 Aug 2026

• Predicting continuous amyloid PET levels with CSF and plasma brain-derived p-tau217

  Consulting or advice, Board or leadership role, 1 Aug 2026

• Neurobiological markers across joint profiles of subjective cognitive decline and objective cognitive function in older adults

  Consulting or advice, 1 Aug 2026

• CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults

  Consulting or advice, Board or leadership role, 1 Aug 2026

• Age-related alterations in plasma biomarkers of relevance to Alzheimer's disease are attenuated in KLOTHO KL-VS heterozygotes

  Consulting or advice, Board or leadership role, 6 Mar 2026

• Unraveling the role of polyamine metabolism in postoperative delirium: insights into biochemical mechanisms and biomarker potential

  Consulting or advice, Board or leadership role, 21 Feb 2026

Sources: pubmed.ncbi.nlm.nih.gov

• Brainstem MRI signal links to an Alzheimer's marker in adults

  medRxiv, 9 Oct 2026

• Blood-based biomarkers of Alzheimer's disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms

  NPJ dementia, 4 Sept 2026

• Mid‐ to Late‐Life Changes in Plasma Biomarkers of Alzheimer's Disease Pathology and Neurodegeneration and Associations with Cortical Thickness: The Atherosclerosis Risk in Communities Study

  AAIC 2025 abstract, 8 Jan 2026

• Acute effects of lactate infusion on metabolism, AD biomarkers, and cognition; the LEAN study

  AAIC 2025 abstract, 8 Jan 2026

• Plasma pTau217 levels and conversion to MCI in the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin ADRC

  AAIC 2025 abstract, 8 Jan 2026

• Childhood neighborhood socioeconomic position and levels of plasma markers of Alzheimer's disease pathology and neurodegeneration in adulthood; the Atherosclerosis Risk in Communities Study

  AAIC 2025 abstract, 7 Jan 2026

• Plasma Aβ40, Aβ42, Aβ42/40 ratio, tau, p ‐tau181, p ‐tau217 and NfL biomarkers to discriminate the prodromal stage of dementia along the continuum of cognitive impairment: Sex differences in the CompAS study

  AAIC 2025 abstract, 7 Jan 2026

• Plasma Neurodegeneration and AD Biomarkers Identify Populations With Rapid Cognitive Decline

  GSA 2025 abstract, 3 Jan 2026

• AD biomarkers in cognitive pre‐frailty: Preliminar results from the CompAS

  AAIC 2025 abstract, 25 Dec 2025

• Comparison of plasma pTau217 assays on different platforms

  AAIC 2025 abstract, 25 Dec 2025

• Increased Plasma Amyloid and Tau Concentrations associated with Decreased Mechanical Integrity of Braak Regions Measured with Magnetic Resonance Elastography

  AAIC 2025 abstract, 25 Dec 2025

• Alzheimer disease blood biomarkers and cognition in midlife

  AAIC 2025 abstract, 25 Dec 2025

• Characterisation of plasma phosphorylated Tau181 in a middle‐aged birth cohort: Associations with cognitive decline, brain structural integrity, and accelerated ageing

  AAIC 2025 abstract, 25 Dec 2025

• Accelerated Aging in the Down Syndrome Brain Indicated by Plasma Biomarkers Showing Greatly Increased Rates of Age‐ and Sex‐Associated Neurodegeneration (UCH‐L1 and NfL) and Astrogliosis (GFAP) and by Heightened Neuronal Apoptosis in a Mouse Model of Down Syndrome

  AAIC 2025 abstract, 25 Dec 2025

• Plasma neurofilament light chain, cognition, and MRI measures in community‐dwelling Hispanics

  AAIC 2025 abstract, 24 Dec 2025

• Compounding Effects of APOE4 and Blood Neurodegenerative Biomarkers on Cognitive Decline in Community‐dwelling Older Adults

  AAIC 2025 abstract, 24 Dec 2025

• Increased Plasma Amyloid and Tau Concentrations associated with Decreased Mechanical Integrity of Braak Regions Measured with Magnetic Resonance Elastography

  AAIC 2025 abstract, 23 Dec 2025

• Demographic associations with plasma biomarkers in the oldest‐old

  AAIC 2025 abstract, 23 Dec 2025

• Streamlining Recruitment for AD Clinical Trials: Concurrent Detection of Cognitive Impairment and Amyloid‐Beta PET Status with a Machine Learning‐Enabled Digital Cognitive Assessment

  AAIC 2025 abstract, 23 Dec 2025

• Plasma neurofilament light chain levels modulate the effects of cognitive intervention: Evidence from a PICMOR randomized controlled trial

  AAIC 2025 abstract, 23 Dec 2025